Recent Company News

• 12:41 PM ET Feb 09, 2026
  

  Transcript Intelligence: Eisai Q3 Earnings Guidance

• 12:40 PM ET Feb 09, 2026
  

  Transcript Intelligence: Eisai Q3 Earnings Themes

• 12:40 PM ET Feb 09, 2026
  

  Transcript Intelligence: Eisai Q3 Earnings Q&A

• 01:37 AM ET Feb 09, 2026
  

  Eisai reports Q3 net income attributable ¥17.20B vs FactSet ¥19.82B [3 est, ¥16.50-26.32B]

• 12:51 AM ET Feb 09, 2026
  

  BioArctic announces BLA for subcutaneous formulation of Leqembi designated for Priority Review in China (SEK 306.80, 0.00)

• 02:25 PM ET Feb 06, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 8-Feb

• 06:08 AM ET Feb 06, 2026
  

  BioArctic receives Q4 royalties of SEK127M, ~ +31% y/y, from sales of Leqembi (SEK 295.20, -9.80)

• 04:02 AM ET Feb 05, 2026
  

  Shanghai Henlius Biotech enters into license agreement with Eisai for HANSIZHUANG (HK$60.35, 0.00)

• 01:01 AM ET Feb 03, 2026
  

  Newron Pharmaceuticals notes publication highlighting clinically meaningful benefits of evenamide as an adjunctive treatment in schizophrenia (CHF 20.00, 0.00)

• 01:55 PM ET Jan 30, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 1-Feb